Skip to main content
. Author manuscript; available in PMC: 2016 Feb 1.
Published in final edited form as: Lancet Oncol. 2014 Jan;15(1):e42–e50. doi: 10.1016/S1470-2045(13)70334-6

Table 1.

Length of time from commencement of enrollment until publication for clinical trials of perioperative treatments for NSCLCs

Trial Disease Setting Outcome measured Time from enrollment
to publication of data
IALT(1) NSCLCs Adjuvant therapy Overall Survival 9 years
JRB.10(6) NSCLCs Adjuvant therapy Overall Survival 11 years
ANITA(2) NSCLCs Adjuvant therapy Overall Survival 12 years
CALGB 9633(7) NSCLCs Adjuvant therapy Overall Survival 12 years
LU22(8) NSCLCs Neoadjuvant therapy Overall Survival 10 years (closed early)
SWOG9900(9) NSCLCs Neoadjuvant therapy Overall Survival 11 years (closed early)
NATCH(10) NSCLCs Neoadjuvant versus
adjuvant therapy		 Overall Survival 10 years
GLCCG(11) NSCLCs Neoadjuvant
chemotherapy versus
CRT		 Overall Survival 13 years